NOVARTIS PHARMACEUTICALS CORP

NOVARTIS PHARMACEUTICALS CORP (United States) holds 9 active US FDA Type II Drug Master Files and 13 inactive, has DMF or CEP filings on record for 11 active ingredients and is linked to 16 FDA-registered manufacturing sites. 50 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “NOVARTIS PHARMACEUTICALS CORP: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/novartis-pharmaceuticals-corp

Overview

NOVARTIS PHARMACEUTICALS CORP is an active pharmaceutical ingredient (API) supplier with 9 active FDA Type II Drug Master Files, covering AMLODIPINE BESYLATE (PROCESS 2); FLUVASTATIN DRUG SUBSTANCE; LIORESAL INTRATHECAL AMPULS/BACLOFEN; MYCOPHENOLIC ACID, DRUG SUBSTANCE INTERMEDIATE; RAPAMYCIN; TERBINAFINE.

Core services & business areas

API ManufacturingPharmaceutical Manufacturing

Active ingredients with DMF or CEP filings

Substances for which NOVARTIS PHARMACEUTICALS CORP holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

NOVARTIS PHARMACEUTICALS CORP holds 9 active (22 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • RAPAMYCINActive2014-03-21
  • TERBINAFINEActive2013-06-07
  • TOPOTECAN HYDROCHLORIDEActive2011-02-02
  • VALSARTAN DRUG SUBSTANCEActive2010-07-02
  • FLUVASTATIN DRUG SUBSTANCEActive2010-06-30
  • AMLODIPINE BESYLATE (PROCESS 2)Active2009-07-21
  • MYCOPHENOLIC ACID, DRUG SUBSTANCE INTERMEDIATEActive2008-08-20
  • RAPAMYCINActive2001-11-13
  • LIORESAL INTRATHECAL AMPULS/BACLOFENActive1992-04-15
  • SMT487 ACETATE (EDOTREOTIDE)Inactive2008-08-08
  • PULMONARY DRUG DELIVERY SYSTEM (PDDS) CLINICALInactive2007-10-31
  • PULMOSPHERE(R) PLACEBO INHALATION POWDERInactive2005-09-02
  • MYCOPHENOLIC ACIDInactive2002-01-24
  • RIFAMPINInactive1998-09-01
  • MANUFACTURING SITE, FACILITIES, PERSONNEL AND OPERATING PROCEDURES IN STEIN, SWITZERLAND.Inactive1997-12-16
  • TESSALON DRUG SUBSTANCE, (BENZONATATE, USP)Inactive1997-03-14
  • MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURE IN ORLEANS-LA SOURCE, FRANCE.Inactive1995-10-20
  • TESSALON DRUG SUBSTANCEInactive1991-03-13
  • STARTING MATERIALS 1 & 3, IN NEW JERSEY AND SWITZERLANDInactive1988-06-07
  • PYRILAMINE BASEInactive1986-09-24
  • PYRILAMINE MALEATEInactive1986-09-24
  • PERSONNEL, FACILS & GEN OPERATING PROCEDURES AT EAST HANOVER, NJ.Inactive1980-06-16

Registered manufacturing sites (16)

Physical sites registered with the US FDA and resolved to NOVARTIS PHARMACEUTICALS CORP, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

50 FDA enforcement records linked to this company.

  • recall — Class II2026-08-19

    Failed Dissolution Specifications

  • 4832026-02-06

    Cleaning / Sanitizing / Maintenance

  • 4832026-02-06

    Investigations of discrepancies, failures

  • 4832026-02-06

    Procedures for sterile drug products

  • 4832024-08-08

    Procedures not in writing, fully followed

  • 4832024-08-08

    Procedures for sterile drug products

  • 4832024-08-08

    Computer control of master formula records

  • 4832024-08-08

    Scientifically sound laboratory controls

  • recall — Class I2023-12-13

    Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals

  • recall — Class I2023-09-27

    Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals.

  • recall — Class II2022-10-05

    CGMP deviations: Out of specification results obtained during routine stability testing for ethanol content.

  • recall — Class III2022-06-15

    Failed Impurities/Degradation Specifications.

  • recall — Class III2022-06-15

    Failed Impurities/Degradation Specifications.

  • recall — Class III2022-06-15

    Failed Impurities/Degradation Specifications.

  • recall — Class III2022-06-15

    Failed Impurities/Degradation Specifications.

  • 4832019-08-21

    Procedures for sterile drug products

  • 4832019-08-21

    Extent of discrepancy, failure investigations

  • 4832019-08-21

    Items to cover on annual reviews

  • 4832019-08-21

    Control procedures to monitor and validate performance

  • recall — Class I2019-05-29

    Cross Contamination with Other Products: product is being recalled due to possible cross-contamination with peanut flour.

  • recall — Class III2017-05-03

    Failed Impurities/Degradation Specifications.

  • recall — Class III2017-05-03

    Failed Impurities/Degradation Specifications.

  • recall — Class III2015-09-23

    Failed Dissolution Specifications: Product is being recalled due to out of specification (above specification) result obtained at 6-hour dissolution time point during the 12-month stability testing.

  • recall — Class III2015-06-24

    Failed Stability Specification: out of specification result obtained for the Particle Size Distribution test during stability testing.

  • recall — Class III2015-06-24

    Failed Stability Specification: out of specification result obtained for the Particle Size Distribution test during stability testing.

  • recall — Class III2014-08-13

    Failed Tablet/Capsule Specifications: Ink identification had rubbed off tablets in transit making them illegible to pharmacists and consumers.

  • recall — Class III2014-06-25

    Failed Stability Specification; out of specification result for particle size distribution during stability testing

  • recall — Class III2014-04-16

    Labeling: Incorrect or Missing Package Insert; The back of the Medication Guide attached to the Package Insert for Ritalin Tablets was printed with information related to Ritalin SR (Sustained Release) Tablets. Both products, Ritalin Tablets and Ritalin SR Tablets utilize a combined Package Insert. The individual Medication Guides are attached to the Package Insert via a perforation. Although t

  • recall — Class III2014-04-16

    Labeling: Incorrect or Missing Package Insert; The back of the Medication Guide attached to the Package Insert for Ritalin Tablets was printed with information related to Ritalin SR (Sustained Release) Tablets. Both products, Ritalin Tablets and Ritalin SR Tablets utilize a combined Package Insert. The individual Medication Guides are attached to the Package Insert via a perforation. Although t

  • recall — Class II2013-12-18

    Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottles of Diovan, Exforge, Exforge HCT,Lescol XL, Stalevo, Tekturna and Tekturna HCT Tablets due to contamination with Darocur 1173 a photocuring agent used in inks on shrink-wrap sleeves.

  • recall — Class II2013-12-18

    Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottles of Diovan, Exforge, Exforge HCT,Lescol XL, Stalevo, Tekturna and Tekturna HCT Tablets due to contamination with Darocur 1173 a photocuring agent used in inks on shrink-wrap sleeves.

  • recall — Class II2013-12-18

    Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottles of Diovan, Exforge, Exforge HCT,Lescol XL, Stalevo, Tekturna and Tekturna HCT Tablets due to contamination with Darocur 1173 a photocuring agent used in inks on shrink-wrap sleeves.

  • recall — Class II2013-12-18

    Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottles of Diovan, Exforge, Exforge HCT,Lescol XL, Stalevo, Tekturna and Tekturna HCT Tablets due to contamination with Darocur 1173 a photocuring agent used in inks on shrink-wrap sleeves.

  • recall — Class II2013-12-18

    Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottles of Diovan, Exforge, Exforge HCT,Lescol XL, Stalevo, Tekturna and Tekturna HCT Tablets due to contamination with Darocur 1173 a photocuring agent used in inks on shrink-wrap sleeves.

  • recall — Class II2013-12-18

    Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottles of Diovan, Exforge, Exforge HCT,Lescol XL, Stalevo, Tekturna and Tekturna HCT Tablets due to contamination with Darocur 1173 a photocuring agent used in inks on shrink-wrap sleeves.

  • recall — Class II2013-12-18

    Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottles of Diovan, Exforge, Exforge HCT,Lescol XL, Stalevo, Tekturna and Tekturna HCT Tablets due to contamination with Darocur 1173 a photocuring agent used in inks on shrink-wrap sleeves.

  • recall — Class II2013-12-18

    Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottles of Diovan, Exforge, Exforge HCT,Lescol XL, Stalevo, Tekturna and Tekturna HCT Tablets due to contamination with Darocur 1173 a photocuring agent used in inks on shrink-wrap sleeves.

  • recall — Class II2013-12-18

    Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottles of Diovan, Exforge, Exforge HCT,Lescol XL, Stalevo, Tekturna and Tekturna HCT Tablets due to contamination with Darocur 1173 a photo curing agent used in inks on shrink-wrap sleeves.

  • recall — Class II2013-12-18

    Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottles of Diovan, Exforge, Exforge HCT,Lescol XL, Stalevo, Tekturna and Tekturna HCT Tablets due to contamination with Darocur 1173 a photocuring agent used in inks on shrink-wrap sleeves.

  • recall — Class II2013-12-18

    Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottles of Diovan, Exforge, Exforge HCT,Lescol XL, Stalevo, Tekturna and Tekturna HCT Tablets due to contamination with Darocur 1173 a photocuring agent used in inks on shrink-wrap sleeves.

  • recall — Class II2013-12-18

    Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottles of Diovan, Exforge, Exforge HCT,Lescol XL, Stalevo, Tekturna and Tekturna HCT Tablets due to contamination with Darocur 1173 a photo curing agent used in inks on shrink-wrap sleeves.

  • recall — Class II2013-12-18

    Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottles of Diovan, Exforge, Exforge HCT,Lescol XL, Stalevo, Tekturna and Tekturna HCT Tablets due to contamination with Darocur 1173 a photocuring agent used in inks on shrink-wrap sleeves.

  • recall — Class II2013-12-18

    Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottles of Diovan, Exforge, Exforge HCT,Lescol XL, Stalevo, Tekturna and Tekturna HCT Tablets due to contamination with Darocur 1173 a photocuring agent used in inks on shrink-wrap sleeves.

  • recall — Class II2013-12-18

    Chemical Contamination: Novartis Pharmaceuticals Corporation has recalled physician sample bottles of Diovan, Exforge, Exforge HCT,Lescol XL, Stalevo, Tekturna and Tekturna HCT Tablets due to contamination with Darocur 1173 a photocuring agent used in inks on shrink-wrap sleeves.

  • 4832012-12-19

    Review of representative number of batches

  • 4832012-12-19

    Absence of Written Procedures

  • 4832012-01-31

    Theoretical yield statement including percentages

  • 4832012-01-31

    Establishment of time limitations

  • 4832012-01-31

    Procedures not in writing, fully followed

  • 4832010-12-21

    Testing and release for distribution

For suppliers

Is this NOVARTIS PHARMACEUTICALS CORP?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.